Back to top

vaccines: Archive

Zacks Equity Research

Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

GSKNegative Net Change JNJPositive Net Change MRNAPositive Net Change NVAXNegative Net Change

Kinjel Shah

COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.

REGNPositive Net Change JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Mark Vickery

Powell Vows to Speed-Up Taper, Market Falls

Shares plummeted for the second trading day in the last three, with the Dow finishing down -652 points, -1.86%, the S&P 500 -1.90% and the Nasdaq dropping -1.55% on the day.

CRMNegative Net Change ADPNegative Net Change MRNAPositive Net Change HPEPositive Net Change

Sweta Jaiswal, FRM

Moderna ETFs Rallying on COVID-19 Vaccine News to Combat Omicron

Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.

MRNAPositive Net Change IBBNegative Net Change BBHNegative Net Change IDNANegative Net Change GERMNegative Net Change

Mark Vickery

Reversal on Omicron Prospects Send Markets Down

Moderna's (MRNA) Stephane Bancel told the Financial Times that the scientists he's been talking to say fighting Omicron is "not going to be good."

MRNAPositive Net Change QQQNegative Net Change SPYNegative Net Change DIANegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXPositive Net Change

Mark Vickery

Nice Relief Rally on Biotech Assurances, Home Sales Data

The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.

MRNAPositive Net Change NVAXNegative Net Change

Mark Vickery

Nice Relief Rally on Biotech Assurances, Home Sales Data

The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.

MRNAPositive Net Change NVAXNegative Net Change

John Blank

Will Bond Tapering Speed Up? Hold? Global Week Ahead

Macro data out in the Global Week Ahead could provide the spark: one that re-ignites risk-free U.S. Treasury bond market rates, heedless of this fresh COVID variant worry.

HDPositive Net Change JDNegative Net Change

Zacks Equity Research

Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

GSKNegative Net Change NVAXNegative Net Change DTILNegative Net Change ISEENegative Net Change

Mark Vickery

Will Cyber Monday Rescue Holiday Shopping from Omicron Fears?

Pre-market futures this morning are buoyant, indicating market participants may have overreacted to the Friday news.

AMZNNegative Net Change ADPNegative Net Change PFEPositive Net Change

Mark Vickery

Black Friday Meets "Black Friday:" New Covid Variant Hits Markets

A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.

PFEPositive Net Change UALNegative Net Change MRNAPositive Net Change TRIPNegative Net Change NCLHNegative Net Change ZMNegative Net Change PTONNegative Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11

Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe

JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

J&J (JNJ) Gets First Full Approval for COVID Jab in Canada

Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.

JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Sweta Jaiswal, FRM

Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.

PFEPositive Net Change PJPNegative Net Change IHENegative Net Change FDLPositive Net Change IEIHNegative Net Change BNTXPositive Net Change